David Hoang
Stock Analyst at Deutsche Bank
(4.72)
# 760
Out of 5,184 analysts
130
Total ratings
53.3%
Success rate
25.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgraded: Hold | $14 → $18 | $13.33 | +35.03% | 24 | Nov 10, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $267 → $245 | $129.36 | +89.39% | 11 | Nov 3, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Hold | $165 → $175 | $150.57 | +16.23% | 13 | Nov 3, 2026 | |
| CLYM Climb Bio | Initiated Coverage: Buy | $28 | $9.19 | +204.68% | 1 | Oct 20, 2026 | |
| HRMY Harmony Biosciences Holdings | Reiterated: Hold | $39 → $42 | $32.59 | +28.87% | 9 | Oct 1, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $38 → $31 | $17.11 | +81.18% | 12 | Sep 25, 2026 | |
| XENE Xenon Pharmaceuticals | Downgraded: Hold | $90 → $46 | $37.04 | +24.19% | 10 | Sep 18, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiated Coverage: Hold | $120 | $112.36 | +6.80% | 1 | Aug 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $287 → $300 | $230.26 | +30.29% | 8 | Aug 26, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $135 → $127 | $93.47 | +35.87% | 5 | Aug 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $120 | $115.31 | +4.07% | 1 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $35 | $18.45 | +89.70% | 10 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $20 | $12.39 | +61.42% | 2 | Jun 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $420 → $374 | $300.43 | +24.49% | 9 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $45 | $44.94 | n/a | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | $0.1865 | n/a | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $6.25 | n/a | 3 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $1.53 | n/a | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $220 | $143.82 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $41.37 | n/a | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $24 → $3 | $10.72 | n/a | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $0.281 | n/a | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $73 | $308.89 | n/a | 1 | Mar 12, 2020 |
Sarepta Therapeutics
Nov 10, 2026
Upgraded: Hold
Price Target: $14 → $18
Current: $13.33
Upside: +35.03%
Axsome Therapeutics
Nov 3, 2026
Reiterated: Buy
Price Target: $267 → $245
Current: $129.36
Upside: +89.39%
Neurocrine Biosciences
Nov 3, 2026
Reiterated: Hold
Price Target: $165 → $175
Current: $150.57
Upside: +16.23%
Climb Bio
Oct 20, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $9.19
Upside: +204.68%
Harmony Biosciences Holdings
Oct 1, 2026
Reiterated: Hold
Price Target: $39 → $42
Current: $32.59
Upside: +28.87%
Acadia Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $38 → $31
Current: $17.11
Upside: +81.18%
Xenon Pharmaceuticals
Sep 18, 2026
Downgraded: Hold
Price Target: $90 → $46
Current: $37.04
Upside: +24.19%
Rhythm Pharmaceuticals
Aug 27, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $112.36
Upside: +6.80%
Jazz Pharmaceuticals
Aug 26, 2026
Reiterated: Buy
Price Target: $287 → $300
Current: $230.26
Upside: +30.29%
Spyre Therapeutics
Aug 26, 2026
Reiterated: Buy
Price Target: $135 → $127
Current: $93.47
Upside: +35.87%
Jul 29, 2026
Initiated Coverage: Hold
Price Target: $120
Current: $115.31
Upside: +4.07%
Jul 16, 2026
Rated: Buy
Price Target: $31 → $35
Current: $18.45
Upside: +89.70%
Jun 26, 2026
Rated: Buy
Price Target: $65 → $20
Current: $12.39
Upside: +61.42%
Jun 2, 2026
Reiterated: Buy
Price Target: $420 → $374
Current: $300.43
Upside: +24.49%
Nov 13, 2025
Reiterated: Buy
Price Target: $52 → $45
Current: $44.94
Upside: n/a
Jul 25, 2024
Initiated Coverage: Buy
Price Target: $7
Current: $0.1865
Upside: n/a
Jul 17, 2024
Reiterated: Buy
Price Target: $16
Current: $6.25
Upside: n/a
Mar 6, 2024
Reiterated: Buy
Price Target: $16
Current: $1.53
Upside: n/a
Apr 26, 2023
Initiated Coverage: Hold
Price Target: $220
Current: $143.82
Upside: n/a
Apr 26, 2023
Initiated Coverage: Buy
Price Target: $80
Current: $41.37
Upside: n/a
Dec 7, 2022
Downgraded: Hold
Price Target: $24 → $3
Current: $10.72
Upside: n/a
Sep 30, 2020
Reiterated: Buy
Price Target: $19
Current: $0.281
Upside: n/a
Mar 12, 2020
Initiated Coverage: Buy
Price Target: $73
Current: $308.89
Upside: n/a